Executive Summary
Across 50 SEC filings dated November 3, 2026, the dominant theme is divergence between headline earnings growth and underlying cash generation or balance-sheet quality.
Several companies posted strong reported profits (Palantir revenue +95.9% YoY, Atlantic Union net income +48% YoY, Lumentum revenue +136.5% YoY) while operating cash flow, free cash flow, or book value deteriorated (Atlas Energy operating cash flow -63% over nine months, GXO free cash flow down to $85M from $187M, Amerant equity down to $840.8M from $938.8M on OCI losses). Distress and restructuring signals are concentrated: Karyopharm filed a prepackaged Chapter 11, Mercer International agreed a restructuring support deal with existing common stock being cancelled, QuidelOrtho cut its EPS guidance high end from $0.90 to $0.70 and launched an $80M+ cost program, and Stewards, Pelthos and Visium show governance or control-related situations. Capital markets activity is heavy, including a $500M WAB notes offering at 5.900% and Sands China's $1.0B notes at 6.400%-6.700%, which lock in materially higher coupons. Several filings (13F-HRs, routine ASX disclosures, pro forma exhibits) are informational and carry little actionable signal, so the digest weights the 15-20 filings with quantified trend data most heavily.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 13F · 8-K · 10-Q · 425 · Schedule 13D · DEF 14A
Tracking the trend? Catch up on the prior US SEC Filings Daily Market Digest digest from November 02, 2026.
Investment Signals (13)
- Palantir Technologies ↓ (BULLISH)▲
Q3 revenue +95.9% YoY to $2.31B, operating income nearly tripled to $1.08B (46.9% margin), accumulated deficit shrank to $502.0M from $3.56B at year-end 2025
- Lumentum Holdings ↓ (BULLISH)▲
Revenue +136.5% YoY to $1,262.6M, diluted EPS $3.54 vs $0.05, operating cash flow rose to $267.7M from $57.9M, though cash fell $771M in the quarter on buybacks, convertible settlements and capex
- Atlantic Union Bankshares ↓ (MIXED LEANING BULLISH)▲
Q3 net income +48% YoY to $136.6M and nine-month net income $419.8M vs $161.7M, but AOCI loss widened to $(402.4)M and short-term borrowing interest rose ~12x YoY, signaling funding strain
- Match Group ↓ (BULLISH)▲
Q3 net income +8.5% and diluted EPS +17.7% on a 10.1% cut in operating costs despite revenue -2.5% YoY; $337.0M of YTD buybacks supports per-share returns
- Archrock ↓ (BULLISH)▲
Net income +18.6% YoY to $84.5M, leverage cut to 2.5x from 3.1x, quarterly dividend raised ~10% YoY to $0.23, FY2026 Adjusted EBITDA guidance reaffirmed at $865-$885M, but adjusted FCF down 56.4% YoY
- Black Stone Minerals ↓ (BULLISH)▲
Distribution raised 9% QoQ and 17% since Q1 2026 to $0.35/unit with 1.25x coverage; Adjusted EBITDA +18% YoY to $104.1M, offset by a $30.2M derivative loss driving net income down to $52.4M
- GXO Logistics ↓ (BEARISH)▲
Organic revenue growth of 6.4% is its fastest in over three years, but operating cash flow fell to $156M from $232M and free cash flow to $85M from $187M; $84M of buybacks were funded against $2.5B net debt
- Atlas Energy Solutions ↓ (BEARISH)▲
Nine-month operating cash flow fell 63% to $41.8M while capex nearly tripled to $367.8M and cash dropped to $22.3M; Q3 gross profit -78% YoY
- Xometry ↓ (MIXED)▲
Revenue +39.7% YoY to $252.4M and operating income turned positive at $0.06M, but gross margin slipped to 39.1% from 39.9% and receivables rose to $152.2M from $97.4M, a $55.1M cash drag
- Amerant Bancorp ↓ (MIXED)▲
Q3 net income +74.3% YoY to $25.7M and $20.4M of buybacks YTD cut shares ~3.6%, but a $(95.1)M OCI hit reduced equity to $840.8M from $938.8M
- International General Insurance ↓ (BEARISH)▲
Q3 net income -16.4% and nine-month diluted EPS -22.9% despite NPE +8.6%; combined ratio deteriorated to 85.7% from 76.5% on rising current accident-year losses and a 32% jump in acquisition expenses
- LENZ Therapeutics ↓ (BEARISH)▲
Q3 net loss $30.97M vs $16.70M, total revenue fell to $3.38M from $12.50M, cash plus securities down to $197.30M from $292.35M; first product sales of $5.99M nine-month are not yet offsetting SG&A up 29.9%
- Fusemachines ↓ (BEARISH)▲
Q3 operating expenses +57.7% YoY, net loss $4.62M vs $1.17M, nine-month revenue -4.5%, cash fell to $1.45M from $4.22M
Risk Flags (11)
- Karyopharm Therapeutics/Restructuring↓ [HIGH RISK]▼
Prepackaged Chapter 11 filed in S.D. Texas with voting deadline November 30, 2026; 1L, 1.5L and 2L noteholders and preferred holders support the plan, with general unsecured claims unimpaired
- Mercer International/Equity Wipeout↓ [HIGH RISK]▼
Restructuring support agreements cover ~$1.1B of $1.275B Senior Notes; existing common stock is cancelled, holders receive ~8.5% of new common, Nasdaq delisting expected, plan confirmation targeted within ~45 days
- Atlas Energy Solutions/Liquidity↓ [HIGH RISK]▼
Accumulated deficit widened to $167.8M from $50.3M at year-end 2025, cash at $22.3M, and new convertible notes added while operating cash flow compressed 63%
- Pfizer/Impairment Drag↓ [ELEVATED RISK]▼
Nine-month net income fell 39.7% to $5,681M on $4,487M of asset write-offs and impairments; Q3 R&D +18.4% and Other deductions of $4,866M vs $2,210M prior year
- QuidelOrtho/Guidance Cut↓ [HIGH RISK]▼
Q3 revenue -12% YoY to $619M with Point of Care -27%, adjusted EPS guidance high end lowered to $0.70 from $0.90; nine-month GAAP net loss $238.5M and operating cash flow -$124.0M
- Pelthos Therapeutics/Control Dilution↓ [ELEVATED RISK]▼
Ligand's $33.75M purchase and Castle Creek merger would push Ligand to 49.9% beneficial ownership with two Castle Creek board designees and expanded board to ten, creating a control-shift risk for minority holders
- Visium Technologies/Governance Conflict↓ [ELEVATED RISK]▼
Director and officer Mark Lucky (9.43% holder) has suspended a Good Reason resignation, corrected a prior erroneous amendment, and the rescinded 1-for-1,500 reverse split and lapsed separation talks signal board-management friction
- Picard Medical/Related-Party Liquidity↓ [HIGH RISK]▼
CEO-Chair Richard Fang's affiliates hold ~$1.2M of related-party loans, with earliest Series II loans already due after the $1.0M external funding milestone was missed; company is funding operations through insider borrowing
- Stewards, Inc./Financing Terms↓ [ELEVATED RISK]▼
Convertible note financing with CROM for a 330-unit multifamily acquisition includes participation rights in subsequent placements and restrictions on use of proceeds; Hawthorne PSA terminated September 17, 2026
- Crown Equity Holdings/Going Concern↓ [HIGH RISK]▼
Quarterly revenue of $102 (-63% YoY), cash of $1,137 vs total liabilities of $417,495, stockholders' deficit $407,778, and related-party borrowings funding operations
- Sands China/Higher Cost of Debt [ELEVATED RISK]▼
$1.0B refinancing retires a 2.300% 2027 note with 6.400% and 6.700% notes due 2032-2033, a meaningful increase in cost of debt for LVS's Macau subsidiary
Opportunities (10)
- Palantir Technologies/Earnings Momentum↓ (OPPORTUNITY)◆
Deferred revenue (current) rose to $661.3M from $409.0M and customer deposits to $512.6M from $357.1M, signaling forward revenue visibility beyond the Q3 print
- Black Stone Minerals/Caturus Expansion↓ (OPPORTUNITY)◆
Development agreement expanded by 730,000 gross acres to 950,000 total, with minimum annual commitments rising from 8,000 to 33,600 net lateral feet, supporting multi-year volume growth
- EagleRock Land/Guidance Raise↓ (OPPORTUNITY)◆
Full-year 2026 Adjusted EBITDA guidance raised to $133-137M on Intrepid Ranch and organic growth, with Q3 Adjusted EBITDA margin 78.5% and new Double Eagle V dedication of ~35,000 acres
- Archrock/Shareholder Yield↓ (OPPORTUNITY)◆
Dividend raised ~10% YoY to $0.23 and leverage cut to 2.5x from 3.1x, with FY2026 Adjusted EBITDA guidance reaffirmed at $865-$885M, giving room for further capital returns
- GXO Logistics/Investor Day Catalyst↓ (OPPORTUNITY)◆
Investor Day on November 16, 2026 follows organic growth of 6.4% and reaffirmed FY2026 guidance (adjusted EBITDA $945M-$965M, EPS $2.95-$3.15); a cash-conversion plan could re-rate shares
- Match Group/Margin Expansion↓ (OPPORTUNITY)◆
Cost of revenue fell 16.4% and G&A fell 37.7% YoY in Q3, and nine-month net income rose 26.7% to $511.7M despite flat revenue, indicating operating leverage on a flat top line
- Summit Hotel Properties/Guidance Raise↓ (OPPORTUNITY)◆
Q3 pro forma RevPAR +7.2%, hotel EBITDA +14.4%, Adjusted FFO +13.9% to $0.20 per diluted share, with FY2026 Adjusted EBITDAre and Adjusted FFO guidance raised
- LTC Properties/Portfolio Repositioning↓ (OPPORTUNITY)◆
Q3 revenue +66% YoY to $115.2M as communities converted to the SHOP segment; $323.9M gain on sale and cash rose to $183.0M, funding a $2.46B real property base
- Alphega Innovations/Contingent Capital↓ (OPPORTUNITY)◆
$400,000 strategic investment and up to 6,000 earn-out Series B shares tied to a Quinary City IP acquisition, a low-cash, contingent growth option if closings complete
- Westinghouse Air Brake/Financing Certainty↓ (OPPORTUNITY)◆
$500M 5.900% 2037 notes priced under an existing S-3 shelf and underwritten by four major banks, suggesting orderly access to debt markets and refinancing capacity
Sector Themes (6)
- Margin Pressure Despite Top-Line Growth◆
Atlas Energy (gross profit -78% on revenue +3.2%), GXO (cash flow down on revenue +5.7%), Xometry (gross margin -80 bps on revenue +39.7%), Archrock (adjusted gross margin 73%->72%), and IGIC (combined ratio 76.5%->85.7%) show revenue growth that is not converting to cash or margin, a common late-cycle pattern to monitor
- Funding Cost and Refinancing Risk Rising◆
Sands China refinances a 2.300% note with 6.400%-6.700% paper, WAB prices 5.900% 10-year, Atlantic Union's short-term borrowing interest rose ~12x YoY, and Amerant's securities losses reflect rate-driven OCI hits, implying higher debt-service costs across issuers
- Restructuring and Capital Solutions Concentrated in Healthcare◆
Karyopharm (prepackaged Chapter 11), QuidelOrtho ($80M+ cost program, $700.7M prior goodwill impairment), Pfizer ($4.5B write-offs), LENZ (accumulated deficit $331.5M) and Fusemachines show healthcare/life-sciences balance sheets under pressure from impairments and cash burn
- Insider and Controlling-Holder Activity Elevated◆
Ligand (49.9% stake in Pelthos), Wasson (21.6% in ADM Tronics), Lucky (9.43% in Visium), and Fang's related-party loans at Picard Medical highlight concentrated insider or affiliate control, a recurring governance theme in small caps
- Energy Infrastructure Shows Cash Strain Amid Growth◆
Atlas Energy's capex tripled to $367.8M, EagleRock and Black Stone expanded acreage and development commitments, and Archrock reduced horsepower via asset sales while raising its dividend, suggesting capital is being reallocated across the midstream and services chain
- Ratio and Book Value Drift in Financials◆
Amerant equity -10.5% YTD on OCI losses, Atlantic Union AOCI $(402.4)M with flat equity despite strong earnings, and Sands China's higher-cost debt indicate that headline bank and gaming earnings are masking balance-sheet erosion from unrealized securities losses
Watch List (8)
-
Prepackaged Chapter 11 voting deadline 4:00 p.m. CT on November 30, 2026; watch for confirmation hearing and whether general unsecured claims remain unimpaired
-
Plan confirmation expected within ~45 days of filing (around mid-December 2026) and recapitalization targeted by end of 2026; watch Nasdaq delisting timing for common holders
-
Investor Day on November 16, 2026; watch for free-cash-flow conversion targets (current 30%-40%) and capital return commitments versus the $2.5B net debt load
-
Series B and warrant closings subject to stockholder approvals, Form S-4 effectiveness, HSR clearance and NYSE American listing; watch for any move to lift the 49.9% ownership cap
-
Lucky's Good Reason suspension may end after November 25, 2026 on five business days' notice; resignation effective no later than March 1, 2027 if matters remain uncured
- Dominion/NextEra Virginia transaction (Case PUR-2026-00112)👁
Commission decision on conditions including majority-independent board and ten-year headcount limits; a decision could arrive before year-end
-
Investment Rights Agreement, Series B certificate of designation and Quinary City asset closing remain unexecuted; watch for the first filing that actually funds the $400,000 investment
-
Restructuring execution against $80M+ 2027 savings target and whether FY2026 revenue floor of $2.52B holds after Q3's -12% decline
Filing Analyses
(50)
03-11-2026
Myriad Asset Management US LP filed its Form 13F-HR for the quarter ended September 30, 2026, reporting 64 holdings with an aggregate market value of $79,873,000 (approximately $79.9 Million). The portfolio is concentrated in large-cap technology and semiconductor names, including NVIDIA ($4.67 Million), Microsoft ($4.67 Million), and Alphabet ($3.55 Million), alongside sizable positions in international equity ETFs (Franklin FTSE Japan, South Korea, and Taiwan ETFs totaling roughly $9.14 Million) and broad-market ETFs. The filing does not include prior-period comparisons, so quarter-over-quarter changes cannot be assessed from this document.
- · Filing covers period ended September 30, 2026 and was filed November 3, 2026 under SEC file number 028-21197
- · Includes a Micron Technology call and put pair of 3,500 contracts each, reported with identical values of $3,728,000, which may indicate a hedged or options-based position
- · Country-focused exposure via Franklin FTSE Japan, South Korea, and Taiwan ETFs combined value roughly $9.14 Million, a meaningful share of the portfolio
- · Holdings are concentrated in technology and semiconductors, with the top five positions (NVIDIA, Microsoft, Micron, Alphabet, Amazon) each around $3.5 Million to $4.7 Million
03-11-2026
Alphega Innovations Corp entered two agreements on November 3, 2026: a Strategic Cooperation Agreement with Maison Bouvier Inc. (contemplating a US$400,000 strategic investment in common stock, a planned 80/20 NewCo subsidiary, and up to 6,000 contingent Series B Preferred earn-out shares) and an Asset Acquisition Agreement with Summit Strategic Holdings to acquire the Alphega Quinary City intellectual property platform for 1,500,000 initial common shares plus up to 1,000,000 milestone shares. Several key elements remain unexecuted or unfunded as of filing, including the Investment Rights Agreement, the certificate of designation for Series B Preferred, the NewCo formation, and the asset Closing, so the economic impact is largely contingent.
- · Strategic Investment is contingent: no Investment Rights Agreement executed, no funds received, and no shares issued as of filing
- · Earn-out shares vest only after the full US$400,000 Strategic Investment is received and the Board certifies Qualified Transaction Value
- · Series B Preferred terms (1,000:1 conversion, 8% cumulative dividend) are not yet effective; no certificate of designation has been filed
- · Asset acquisition Closing has not occurred; Initial Shares are not yet issued
- · Several third-party trademarks and rights (Quinary City™, TerraSmart™) are excluded or require separate rights-holder instruments; Terra City branding subject to title verification
- · Milestone Shares are tied to three deliverable packages evaluated under a review and resubmission process with defined business-day timelines
- · Potential dilution from up to 2,500,000 common shares to SSH and up to 6,000,000 common shares to Maison Bouvier if all contingencies are met
03-11-2026
QuidelOrtho reported Q3 2026 total revenue of $619 million, down 12% YoY as reported and in constant currency, with Point of Care down 27% on a softer respiratory season and Labs down 6% on China pricing changes. Excluding respiratory, China and U.S. Donor Screening, revenue grew 2%, and Labs and Immunohematology grew outside China. The company also launched a cost transformation and restructuring program targeting over $80 million in annual savings in 2027, and narrowed full-year 2026 guidance, lowering the adjusted diluted EPS range to $0.65-$0.70 from $0.65-$0.90 and revenue to $2.52-$2.54 billion.
- · Operating cash flow was $20M in Q3 2026, versus -$45.5M a year earlier, but nine-month operating cash flow was still -$124.0M
- · Nine-month GAAP net loss was $238.5M versus $1,001.1M in the prior-year period, which included a $700.7M goodwill impairment
- · Adjusted diluted EPS guidance high end was cut from $0.90 to $0.70
- · Restructuring will reorganize the business into two focused units, Core Diagnostics and Point of Care Diagnostics
- · Cash and cash equivalents were $166.4M at September 27, 2026, against total borrowings of about $2.94B ($424.4M current plus $2,512.9M long-term)
- · Current portion of borrowings rose to $424.4M from $178.3M at year-end 2025, a near-term refinancing consideration
03-11-2026
St. Louis Trust Co filed its Form 13F-HR for the quarter ended September 30, 2026, disclosing equity holdings across roughly 184 securities with an aggregate reported value of approximately $960.3 Million (the filing reports values in thousands of dollars, and the header total of 960285042 corresponds to about $960.3 Billion when read as dollars, so the unit basis should be verified against the raw table). The portfolio is concentrated in broad-market, large-cap, and international index ETFs, with the largest positions including State Street SPDR S&P 500 ETF Trust, Vanguard S&P 500 ETF, Vanguard Total Stock Market, and iShares Russell 1000 ETF. This is a routine regulatory holdings disclosure with no reported change in direction, and the filing itself contains no period-over-period comparison.
- · Filing covers the period ended September 30, 2026, filed November 3, 2026, under SEC file number 028-17178
- · Largest reported single position by value is State Street SPDR S&P 500 ETF Trust (about $101.6 Million on the OTR line plus $10.6 Million SOLE, as reported)
- · Portfolio is heavily weighted toward ETFs and index funds rather than individual operating-company stocks
- · Filer reports zero other included managers and identifies the Treasurer as the signatory
03-11-2026
Altaba Inc. announced that its Board approved a partial liquidating distribution of $0.36 per share, totaling $187,024,091 in aggregate, payable November 13, 2026. The distribution follows court-supervised wind-up proceedings and IRS-approved reductions to a security account totaling approximately $167 million, plus about $44 million in additional funds (interest and refunds). Further distributions remain subject to future announcements and ongoing contingent tax and litigation matters.
- · Liquidating distribution payable November 13, 2026
- · Fund dissolved by certificate filed October 4, 2019, after stockholder approval of the Plan on June 27, 2019
- · Wind-up proceedings commenced May 28, 2020; IRS claims removed to federal court June 18, 2020
- · District of Delaware order establishing IRS security account entered October 26, 2020
- · Further liquidating distributions to be disclosed in future press releases or SEC filings; amounts and timing remain uncertain
- · Fund is an investment company, so forward-looking statements are excluded from PSLRA safe harbor protections
03-11-2026
Endowment Wealth Management, Inc. (Appleton, WI; CIK 0001904477) filed its Form 13F-HR on November 3, 2026, reporting equity holdings as of September 30, 2026 with 196 listed positions and an aggregate reported portfolio value of approximately $292.3 billion ($292,279,378 thousand per the cover page summary). The filing is a combination report covering holdings managed with Envestnet Asset Management Inc (SEC file 028-13411). No prior-period comparison is included in the filing, so period-over-period changes cannot be assessed from this document alone.
- · Largest disclosed single holdings by market value include ETF positions such as iShares Core S&P Total U.S. Stock Market ETF (~$17.1 billion) and iShares Core S&P U.S. Growth ETF (~$7.4 billion), indicating a heavy concentration in broad-market and ETF vehicles rather than individual stocks
- · Single-stock positions are comparatively small: Circle Internet Group holds 58,404 shares (~$4.8 billion), the largest individual common stock position identified, followed by Apple (~$1.4 billion) and NVIDIA (~$9.2 billion when combined across lines), with NVIDIA's combined SOLE position at 40,338 shares (~$9.2 billion)
- · The portfolio shows notable exposure to actively managed and thematic ETFs (e.g., Global X Artificial Intelligence ETF ~$1.6 billion, First Trust Low Duration Opportunities ETF ~$3.3 billion, Invesco Ultra Short Duration ETF ~$3.4 billion)
- · Several positions are held through the OTR 1 (other managers) category, which the filing attributes to a different reporting manager sub-account, while the majority are held with sole investment discretion (SOLE)
- · Small-cap and speculative holdings are present, including BigBear.ai Holdings (~$32 thousand), Recursion Pharmaceuticals (~$56 thousand), Vista Gold (~$34 thousand), and Ready Capital (~$29 thousand), which together represent a very small share of total value
- · The filing does not contain a prior-quarter comparison, so no quarter-over-quarter changes in position size, new buys, or exits can be determined from this document
03-11-2026
Atlas Energy Solutions reported a Q3 2026 net loss of $45.1 million ($0.36 per share) versus a $23.7 million loss in Q3 2025, as total revenue rose 3.2% year over year to $267.8 million while gross profit fell 78% to $5.2 million. For the nine months, net loss widened to $117.5 million from $28.1 million, and revenue declined 2.3% to $826.5 million. Rental revenue grew strongly, but product revenue fell and cost pressure compressed margins; cash fell to $22.3 million as capital spending and new convertible notes reshaped the balance sheet.
- · Net cash provided by operating activities fell to $41.8M in 9M 2026 from $113.6M in 9M 2025, a 63% decline.
- · Capital expenditures on PP&E rose to $367.8M from $126.5M, nearly tripling year over year.
- · Accumulated deficit widened to $167.8M from $50.3M at year-end 2025.
- · Stockholders' equity declined to $1,076.6M from $1,208.9M at year-end 2025, partly from a $39.0M capped call purchase net of tax.
- · Total liabilities rose 44% to $1,468.6M from $1,019.5M, driven by long-term debt increasing to $940.8M.
- · No dividends were paid in 2026 YTD, versus $92.3M in dividends paid in 9M 2025.
- · Other long-term assets jumped to $246.1M from $1.2M, a large balance-sheet change that warrants review in the notes.
- · Operating income was a loss of $95.0M for 9M 2026 versus income of $4.0M in 9M 2025.
- · Credit loss expense was effectively zero in 2026 after $4.2M in 9M 2025.
03-11-2026
GXO Logistics reported Q3 2026 revenue of $3.6 billion, up 5.7% year over year, with organic revenue growth of 6.4%, its fastest in more than three years. However, net income rose only modestly to $65 million from $60 million, adjusted EBITDA was flat at $251 million, and cash flow from operations fell to $156 million from $232 million, with free cash flow down to $85 million from $187 million. Management reaffirmed full-year 2026 guidance and announced an Investor Day on November 16, 2026.
- · Cash flow from operations and free cash flow declined sharply year over year despite revenue growth
- · Net debt of $2.5B against $340M of cash; company repurchased $84M of stock in the quarter
- · Full-year 2026 guidance reaffirmed: organic revenue growth 4%-5%, adjusted EBITDA $945M-$965M, adjusted diluted EPS $2.95-$3.15, free cash flow conversion 30%-40%
- · Conference call scheduled for November 4, 2026 at 8:30 a.m. ET; Investor Day on November 16, 2026 at the NYSE
- · Non-GAAP adjustments include transaction and integration costs, restructuring, a regulatory settlement, and a net loss on divestiture of business
03-11-2026
UTIMCO filed its Form 13F-HR for the quarter ended September 30, 2026, disclosing equity holdings under Section 13(f) of the Exchange Act. The information table lists a large number of positions held with sole investment discretion, including significant stakes in Alphabet, Amazon, Apple, Microsoft, and several ETFs. The filing is a routine periodic holdings disclosure and does not itself report a corporate transaction, earnings result, or regulatory action.
- · Filing covers the period ended September 30, 2026 and was filed November 3, 2026 under file number 028-05714.
- · Cover page reports a total information-table value of approximately $798.08 billion (reported in thousands) across 392 entries, with sole investment discretion over all listed positions.
- · The largest reported single-line position by market value shown in the excerpt is the J.P. Morgan BetaBuilders MSCI US ETF (CUSIP 46641Q738), though its reported value in the excerpt appears inconsistent with its share count and should be verified against the source XML.
- · The excerpt is truncated; the full information table contains additional holdings beyond the portion provided.
03-11-2026
Chilean Cobalt Corp. (COBA) entered into a definitive option agreement on October 28, 2026 to acquire roughly 1,381 hectares of exploitation-level and 2,900 hectares of exploration-level mining concessions in the San Juan mining district of northern Chile, with staged payments totaling $1.5M, $6.0M, $10.0M and $10.0M through December 2028, a $300,000 extension fee already paid, and a 1.5% NSR royalty upon exercise. On October 29, 2026, the company also amended its NeoRe Rare Earth Project earn-in agreement, extending the option expiry to March 31, 2027 and clarifying funding, operatorship and acquisition terms. The filing is largely forward-looking: the company's payment obligations are discretionary, and failure to pay forfeits prior amounts with no further liability, but the agreements require substantial future capital and royalty commitments.
- · Option payments are discretionary; failure to pay forfeits all prior monies ($500K advance and $300K extension fee) and the Option, with no further liability.
- · Option exercise requires a 1.5% NSR royalty for 99 years from first commercial production, with a right of first refusal on initial royalty sales (excluding related parties).
- · NeoRe amendment confirms NeoRe as sole operator with exclusive control over the project, budgets, contractors and permitting since the LOI date.
- · NeoRe Option Expiry Date is March 31, 2027; if no Election Notice is delivered, the acquisition option lapses while NSR and advance-repayment rights survive.
- · Amounts advanced to NeoRe above the $2.104M Tranche 3 cap are refundable interest-free advances, while amounts up to the cap are non-refundable.
- · Definitive NeoRe acquisition requires forfeiture of the earned 2% NSR and issuance of 6,000,000 restricted shares, with lock-ups of 1 year (half) and 2 years (remainder).
03-11-2026
Xometry reported Q3 2026 revenue of $252.4 million, up 39.7% year-over-year from $180.7 million, and swung to operating income of $0.06 million from an operating loss of $11.1 million a year earlier. Net income was $1.9 million versus a $11.6 million loss in Q3 2025. However, gross margin was roughly flat at 39.1% versus 39.9% a year ago, and sales and marketing, operations and support, product development and G&A expenses all rose, with cash used in investing of $326.2 million reflecting heavy securities purchases.
- · Gross margin slipped to 39.1% from 39.9% a year earlier despite revenue growth of nearly 40%
- · Accounts receivable rose to $152.2M from $97.4M at year-end 2025, a cash-flow drag of $55.1M in the nine-month period
- · Other expenses improved to $0.8M in Q3 2026 from $1.6M, while nine-month other expenses were $2.3M versus $19.9M in 2025 (prior year included $16.4M loss on debt extinguishment)
- · Convertible notes shifted: $84.8M now classified as current, reducing long-term convertible notes to $243.6M
- · Donated common stock expense of $4.4M in nine months 2026 versus $2.1M in 2025
- · Capitalized software and PP&E purchases of $38.9M, nearly double the $19.9M in the prior-year period
- · Nine-month diluted EPS of -$0.16 versus -$1.05 in the prior year
03-11-2026
LTC Properties reported Q3 2026 total revenues of $115.2 million, up 66% from $69.3 million in Q3 2025, driven by resident fees and services of $70.5 million (up from $22.2 million) following the conversion of communities into the SHOP segment. Net income attributable to LTC stockholders was $348.1 million versus a loss of $20.0 million a year earlier, mainly due to a $323.9 million gain on sale of real estate. However, rental income declined 1% to $27.5 million, interest income from financing receivables fell 20%, and seniors housing operating expenses rose sharply to $50.8 million, compressing the operating margin.
- · Total assets rose 33.6% to $2.76B from $2.06B at December 31, 2025, driven by real property investments of $2.46B (up from $1.94B).
- · Owned real properties, net, increased to $1.78B from $1.20B, reflecting $737.9M of nine-month property investment partly offset by $469.9M of property sale proceeds.
- · Cash and cash equivalents increased to $183.0M from $14.4M, while the revolving line of credit rose to $429.9M from $252.9M.
- · Nine-month provision/recovery for credit losses was a $0.6M recovery in 2026 versus a $3.6M provision in 2025.
- · Q3 2026 included a $2.3M impairment loss, and no such loss was recorded in Q3 2025.
- · Non-controlling interest distributions related to the sale of properties accounted for as a financing receivable totaled $14.3M in the nine months of 2026.
- · Q3 2025 included a $41.5M write-off of effective interest receivable, which had no 2026 equivalent.
- · Interest expense rose 28.5% in Q3 to $11.3M from $8.8M, and 27.8% year-to-date to $31.6M from $24.7M.
- · Rental income declined in Q3 due to lower rent from property sales and conversion of communities from NNN to SHOP, partially offset by a lease termination fee tied to the sale of 17 SH communities.
- · Dividends per common share were flat at $0.57 quarterly ($1.71 year-to-date) despite the sharp increase in shares outstanding.
03-11-2026
Summit Hotel Properties reported Q3 2026 results with Net loss attributable to common stockholders narrowing to $7.7 million ($0.07 per diluted share) from $11.3 million ($0.11) a year earlier, pro forma RevPAR up 7.2% to $126.17, and pro forma hotel EBITDA up 14.4% to $60.4 million, while Adjusted EBITDAre rose 11.8% to $43.9 million and Adjusted FFO rose 13.9% to $24.2 million ($0.20 per diluted share). Year-to-date results were more mixed: pro forma occupancy declined 0.5% to 74.4%, net loss narrowed to $14.2 million, and pro forma RevPAR rose a more modest 4.0%. Management raised FY2026 guidance ranges for pro forma RevPAR growth, Adjusted EBITDAre, Adjusted FFO, and Adjusted FFO per share.
- · Year-to-date pro forma occupancy declined 0.5% to 74.4%, even as ADR rose 4.5%; the headline Q3 occupancy gain does not offset the YTD decline.
- · YTD pro forma RevPAR growth (4.0%) was roughly 3 percentage points below the Q3 rate (7.2%), indicating the improvement was concentrated in the third quarter.
- · Q3 2026 total revenues grew only 4.8% YoY, well below the 14.4% pro forma hotel EBITDA growth, reflecting margin expansion rather than top-line acceleration.
- · Q3 GAAP FFO per diluted share rose to $0.16 from $0.13, but nine-month FFO of $72.3 million was up 8.9% from $66.4 million.
- · Management cited a quarter-end leverage reduction that drove a further 15 basis point spread cut on $675 million of term loans, saving an estimated $2.4 million annually.
- · Debt maturities are deferred until 2028, with the $200 million term loan extended to February 2028 and two six-month extension options available.
- · Dividends of $0.08 per common share and preferred dividends for Series E, F, and Z are payable November 30, 2026 to holders of record as of November 16, 2026.
- · Management stated there are no assumed acquisitions, dispositions, buybacks, or capital markets activity in FY2026 guidance, so upside depends on operations alone.
- · Hotel sales have been executed at a 4.7% blended cap rate since 2023, with sold hotels achieving RevPAR about 30% below the current portfolio.
03-11-2026
LENZ Therapeutics reported a Q3 2026 net loss of $30.97M (Q3 2025: $16.70M) on total revenue of $3.38M, down from $12.50M in Q3 2025, as selling, general and administrative expenses rose 29.9% to $35.85M. Nine-month net loss widened to $104.38M from $46.23M, and cash plus marketable securities fell to $197.30M at September 30, 2026 from $292.35M at December 31, 2025. Product sales ($2.60M in Q3) were a new revenue stream, but total revenue declined sharply year over year.
- · Product sales of $5.99M for nine months 2026 versus none in 2025, with cost of sales of $1.81M, indicating first commercial product revenue
- · Other comprehensive loss from unrealized securities losses of $1.30M for nine months 2026, versus a $0.03M gain in 2025
- · Accumulated deficit grew to $331.52M from $227.14M at December 31, 2025
- · Operating cash burn of $94.61M for nine months 2026 versus $36.15M in 2025
- · No at-the-market equity raise in 2026; 2025 included $26.07M in net proceeds, so 2026 liquidity is drawn from existing reserves
- · Operating lease liability fell to zero from $0.35M, and property and equipment net declined to $0.64M from $1.19M, including a $0.25M impairment
- · Write-off of nonsalable inventory of $0.56M in nine months 2026
- · Q3 2026 R&D expense was zero versus $3.79M in Q3 2025, while SG&A rose to $35.85M, suggesting a shift toward commercial spend
03-11-2026
Eiger Wealth Management, LLC (San Diego, CA) filed a Form 13F-HR for the quarter ended June 30, 2026, disclosing 12 equity and fund positions with a total reported market value of approximately $3,191,006 thousand (about $3.19 billion) under sole investment discretion. The largest holdings are the Schwab US Large-Cap ETF (32,891 shares, $967,991 thousand) and the iShares MSCI USA Quality Factor ETF ($426,320 thousand), followed by Zentalis Pharmaceuticals and Amazon. The filing is a routine quarterly holdings disclosure with no reported changes in control or regulatory action.
- · All 12 positions are reported with sole voting/investment authority (SOLE), with no shared or other-manager discretion.
- · The filing is a combination report listing co-managers Zacks Investment Management, Horizon Investments, Alta Capital Management, and Goldman Sachs Group as other included managers.
- · Holdings are concentrated: the Schwab US Large-Cap ETF accounts for roughly 30% of the reported total value.
- · Mix spans US equities (Amazon, Zentalis, Immunome, Fate Therapeutics), US factor/growth ETFs, closed-end and emerging-markets fixed income/income funds, and gold/natural resources funds.
03-11-2026
Sands China Ltd., a majority-owned subsidiary of Las Vegas Sands Corp., completed a $1.0 billion private offering of senior unsecured notes, comprising $700 million of 6.400% Senior Notes due 2032 and $300 million of 6.700% Senior Notes due 2033. Proceeds, together with cash on hand, will redeem in full the $700 million 2.300% senior notes due 2027 and repay the outstanding balance on the 2024 SCL Revolving Facility. The notes are structurally subordinated to all liabilities of Sands China's subsidiaries, and the transaction refinances higher-rate-to-lower-maturity debt only partially: the new 2032 and 2033 coupons (6.400% and 6.700%) are substantially above the 2.300% coupon being retired, which implies a meaningfully higher cost of debt going forward.
- · Notes were sold under Rule 144A and Regulation S to Professional Investors and are to be listed on The Stock Exchange of Hong Kong Limited
- · 2032 Notes mature January 8, 2032 with semi-annual interest from January 8, 2027; 2033 Notes mature November 8, 2033 with semi-annual interest from May 8, 2027
- · Covenants limit liens, sale and leaseback transactions, and consolidation, merger or sale of substantially all assets
- · Change of control triggers a repurchase offer at 101% of principal plus accrued interest
- · No Sands China subsidiaries guarantee the Notes
03-11-2026
NextEra Energy and Dominion Energy filed Joint Petitioners' rebuttal testimony with the Virginia State Corporation Commission (Case No. PUR-2026-00112) on November 2, 2026, defending the proposed transfer of control of Virginia Electric and Power Company to NextEra in their business combination. The testimony argues the statutory standard under Va. Code § 56-90 is limited to whether adequate service at just and reasonable rates will be impaired, and it opposes several Staff-proposed conditions, including a majority-independent board and ten-year headcount limits, while reaffirming nearly $2 billion in customer bill credits. The filing does not disclose new financial results, and the deal's outcome remains subject to the Commission's approval.
- · Staff would not oppose approval subject to additional conditions, nearly all of which Joint Petitioners have accepted
- · Joint Petitioners specifically oppose a majority-independent Company board and Staff's proposed ten-year limits on headcount reductions or consolidation
- · Joint Petitioners characterize NextEra Energy Resources as low-risk, long-term contracted, diversified, and structurally separated through non-recourse financing
- · The Commission's ruling will have no ratemaking implications, per the Joint Petitioners
- · A confidential, 'extraordinarily sensitive' version of the testimony was filed under seal separately
03-11-2026
Lumentum Holdings Inc. reported net revenue of $1,262.6M for the three months ended September 26, 2026, up from $533.8M in the year-earlier quarter (+136.5% YoY), with net income of $360.3M versus $4.2M. Income from operations rose to $359.8M from $6.7M, and diluted EPS was $3.54 versus $0.05. Results were supported by a $257.0M... however, cash and cash equivalents fell to $1,272.2M from $2,043.5M at fiscal year-end as the company spent $306.9M on withholding taxes for RSU net share settlement, $493.3M on convertible note conversions, and $229.8M on capital expenditures, while total debt-related current liabilities remained elevated at $1,360.3M.
- · Net cash from operating activities rose to $267.7M from $57.9M, but was more than offset by investing and financing outflows, reducing cash by $771.3M in the quarter
- · Total other income turned positive at $10.5M versus a $(1.5)M expense in the prior-year quarter, driven by $12.9M of interest and other income
- · Research and development expense rose to $191.8M from $81.4M, and stock-based compensation rose to $132.5M from $42.4M
- · Other non-current liabilities increased to $246.4M from $115.2M, and unpaid PP&E in payables rose to $253.5M from $66.6M
- · Total current liabilities declined to $2,391.6M from $2,480.5M, with current debt falling to $1,360.3M from $1,596.9M
- · Common shares outstanding increased to 90.6M from 88.6M, with additional paid-in capital declining to $12,002.0M from $12,430.1M, reflecting RSU tax withholding and convertible note conversions
- · Comprehensive income of $356.8M was reduced by $3.5M of unrealized losses on available-for-sale securities
- · Restructuring charges were nil this quarter versus $8.3M in the prior-year quarter, and a $6.9M gain on sale of a business was recognized
03-11-2026
InnovAge Holding Corp. reported Q1 FY2027 (three months ended September 30, 2026) total revenues of $264.8 million, up 12.1% YoY from $236.1 million, and operating income of $20.2 million, up from $8.3 million a year earlier. Net income attributable to InnovAge rose to $19.6 million ($0.14 per diluted share) versus $8.0 million ($0.06) in the prior-year quarter. However, growth was not uniform: cost of care rose 12.7% and external provider costs rose 6.3%, while corporate G&A declined 3.7% and other service revenue fell sharply (-81%).
- · Operating cash flow more than tripled to $28.7M from $3.9M, aided by a $16.9M reduction in accounts receivable and a $9.1M increase in amounts due to Medicaid and Medicare.
- · Accounts payable and accrued expenses declined $15.0M and reported/estimated claims fell $5.4M, partially offsetting working-capital inflows.
- · Income tax benefit of $0.8M versus a $0.2M provision in the prior year, driving most of the gap between pre-tax and net income.
- · Net income attributable to noncontrolling interests was $1.3M, compared with a $0.4M loss in the prior-year quarter.
- · Long-term debt was essentially stable, with only $0.6M in principal repaid versus a $60.0M refinancing (repayment and reissuance) in the prior-year quarter.
- · Total stockholders' equity rose to $258.0M from $238.8M QoQ, and redeemable noncontrolling interests increased to $31.3M from $30.0M.
- · Capital expenditures were $3.0M, down from $4.1M, and construction in progress grew to $17.4M.
03-11-2026
Optimum Communications, Inc. (OPTU) expanded its Board of Directors from nine to eleven members on October 28, 2026, appointing Elizabeth Abrams and Daniel Silvers as independent directors. The Board also formed a Special Committee comprising the two new directors to evaluate strategic and financial transactions, including financing, restructuring, reorganization, or recapitalization, and to address potential related-party conflicts of interest. Each new director receives a $75,000 monthly fee under an Independent Director Agreement, plus per diem payments for litigation-related and similar activities.
- · Special Committee authority extends to reviewing matters involving actual or potential conflicts of interest with current or former directors, officers, equity holders, or management companies
- · Mr. Silvers' brother is a partner at Ropes & Gray LLP, which the Company retained in the ordinary course for legal services
- · Per diem supplemental payments apply for days involving mediation, arbitration, depositions, or court appearances (or more than four hours of preparation/negotiation)
- · Both directors serve until the next annual stockholder meeting and are deemed independent under NYSE and SEC rules
03-11-2026
Amerant Bancorp reported Q3 2026 net income attributable to the company of $25.7M (vs. $14.8M in Q3 2025, +74.3%) and nine-month net income of $64.6M (vs. $49.7M, +30.0%). However, comprehensive loss for the quarter was $(69.4)M, driven by a $(95.1)M other comprehensive loss from unrealized losses on available-for-sale debt securities, and total stockholders' equity fell to $840.8M from $938.8M at year-end 2025. Net interest income declined 3.9% YoY in the quarter to $90.5M as total interest income fell 7.4%.
- · Q3 2026 provision for credit losses fell to $6.2M from $14.6M, while allowance for credit losses rose to $94.8M from $79.3M at year-end 2025
- · Q3 2026 Class A share repurchases totaled roughly $20.4M (including $18.7M, $16.4M and $2.0M across quarters), reducing outstanding shares by about 3.6% YTD
- · Securities gains turned to a $(26)K loss in Q3 2026 versus a $1.2M gain in Q3 2025; derivative and other operating income also declined sharply YoY
- · Deferred tax assets increased to $78.1M from $35.6M at year-end 2025
- · Net interest margin pressure: interest expense fell 13.1% in Q3 but interest income fell 7.4%, compressing net interest income
- · Company issued $48.4M in senior notes during 2026 and repaid FHLB advances, while cash and equivalents fell 23.1% YTD
03-11-2026
International General Insurance (IGIC) reported Q3 2026 net income of $28.0M, down 16.4% from $33.5M in Q3 2025, and diluted EPS of $0.66 versus $0.75 (-12.0%). For the nine months, net income fell 25.7% to $70.5M from $94.9M and diluted EPS declined to $1.65 from $2.14 (-22.9%). Premium growth was positive, with net premiums earned rising 8.6% in the quarter to $124.5M, but profitability weakened as the combined ratio deteriorated to 85.7% from 76.5% and the accident year combined ratio rose to 92.8% from 85.6%.
- · Q3 2026 current accident year losses prior to CAT rose to 46.3% of NPE from 42.1%, a key driver of margin pressure.
- · Current accident year CAT losses for 9M 2026 reached $53.3M (14.8% of NPE), up from $45.8M, and include losses from the war in the Middle East in the Specialty Short-tail segment.
- · Net policy acquisition expenses rose 32% in Q3 to $24.1M from $18.2M, and G&A expenses rose to $25.2M from $24.4M.
- · Net foreign exchange loss was $0.5M in Q3 2026 versus $6.1M in Q3 2025, a notable improvement, while the 9M 2026 FX loss of $3.9M compared with a $11.1M gain in 9M 2025.
- · Prior-year favorable reserve development was a larger tailwind in 9M 2026 ($39.4M) than in 9M 2025 ($30.0M), partially masking deterioration in the current accident year.
- · Dividends attributable to restricted share awards rose to $1.0M for 9M 2026 from $0.8M.
03-11-2026
Picard Medical, Inc. (NYSE American: PMI) appointed Richard Fang, Ph.D., as permanent, full-time Chief Executive Officer effective October 28, 2026, after he served as Interim CEO since June 18, 2026; he remains Chairman of the Board. The appointment involved no change to his $0.4 million annual salary and no new compensation or award. The filing also discloses related-person borrowings from Dr. Fang-affiliated entities, including $0.7 million at 6% interest due February 28, 2027 and $0.5 million at 0% interest, with the earliest of the latter loans already due on terms to be determined because the Company has not received the required $1.0 million of external funding.
- · Dr. Fang previously served as CEO from September 2021 to July 2023 and has been a Board member since September 2021
- · Related-party loans from Fang-affiliated entities total approximately $1.2M in outstanding principal
- · The earliest Series II loans have already become due on payment terms to be determined, as the two-month window passed without $1.0M in external funding
- · The Company had not received at least $1.0M of external funding as of October 29, 2026
03-11-2026
Westinghouse Air Brake Technologies Corporation (WAB) priced a public offering of $500,000,000 aggregate principal amount of 5.900% Senior Notes due 2037, guaranteed by its subsidiary guarantors and underwritten by BofA Securities, Citigroup Global Markets, PNC Capital Markets and TD Securities. The Underwriting Agreement is dated November 2, 2026, and the offering is being made under an existing Form S-3 shelf registration (File No. 333-299570). The filing contains no disclosure of operating or period-over-period financial results, so no performance metrics are reported in either direction.
- · Notes are guaranteed unconditionally by subsidiary guarantors listed in Schedule B to the Underwriting Agreement
- · Notes will be issued under a 2013 base indenture, as amended, with a fifteenth supplemental indenture dated as of the closing date and U.S. Bank Trust Company as trustee for the Notes
- · Notes will be issued in book-entry form through The Depository Trust Company
- · Press release announcing pricing was issued November 2, 2026 and is furnished as Exhibit 99.1
- · Underwriting Agreement is filed as Exhibit 1.1
03-11-2026
Gregory D. Wasson, through Wasson LLC and G&K Investment Holdings LLC, reported beneficial ownership of 18,750,000 shares of ADM Tronics Unlimited, Inc. (ADMT) on Schedule 13D, representing approximately 21.6% of common stock on an as-adjusted basis including warrants. The stake was acquired in an October 27, 2026 private placement at $0.10 per share with accompanying warrants, and is tied to a planned board reconstitution, a 1-for-20 reverse stock split, and rolling closings targeting approximately $5 million in proceeds by December 31, 2026. Mr. Wasson has not yet joined the board, and the filing states he has no present plans beyond those disclosed.
- · Warrants carry an initial exercise price of $0.10 per share, subject to adjustment
- · Anchor Investor may designate one director while retaining at least 50% of purchased shares
- · Before the Board Effective Time, specified corporate actions require Anchor Investor consent
- · Voting Agreement dated October 26, 2026 may cause a Section 13(d)(3) group with other signatories; the reporting persons disclaim group membership
- · Percentages are calculated before the contemplated 1-for-20 reverse split
03-11-2026
Mark B. Lucky, a director and officer of Visium Technologies, Inc. (VISM), filed Amendment No. 3 to his Schedule 13D, reporting beneficial ownership of 119,746,869 shares (about 9.43% of outstanding common stock, including shares issuable on conversion). The amendment corrects a prior erroneous statement that he had extended his Good Reason cure period, reports a November 2, 2026 letter suspending his Good Reason resignation until the Board constitutes an independent director committee (with resignation effective no later than March 1, 2027 if matters remain uncured), and reports that a proposed 1-for-1,500 reverse stock split was rescinded and not effected. A proposed negotiated mutual separation lapsed without agreement.
- · Amendment No. 2 incorrectly stated an extension of the Good Reason cure period; no extension was ever delivered
- · Reporting person may end the suspension after November 25, 2026 on five business days' written notice
- · Suspension ends immediately if the Issuer terminates him or materially reduces his authority, duties or responsibilities
- · Reporting person has not resigned and will not act for the Issuer on the Notice, cure or his compensation
- · Proposed mutual separation (keeping his securities) lapsed at 5:00 p.m. ET on November 2, 2026 with no agreement reached
- · Reverse split was approved by the Issuer's 8-K filed October 30, 2026 but rescinded by the reporting person as sole director on October 28, 2026
03-11-2026
Ashland reported fourth-quarter fiscal 2026 sales of $498 million, up 4% year over year, driven by a 3% volume increase, with Adjusted EBITDA up 2% to $121 million. Results were mixed: a GAAP net loss of $16 million (versus $32 million net income a year earlier) and a 31% Adjusted EBITDA decline in Specialty Additives weighed on the quarter, while Life Sciences, Personal Care and Intermediates grew. The company also issued fiscal 2027 guidance calling for sales of $1,905-$1,975 million and Adjusted EBITDA of $405-$435 million.
- · Adjusted EBITDA margin contracted 60 basis points to 24.3% from 24.9% despite the sales increase
- · Specialty Additives was flat on sales but its Adjusted EBITDA fell 31%, attributed to lower Hopewell productivity and unfavorable absorption
- · Unallocated and other expense rose to $44M from $11M, driven by restructuring charges and a cumulative translation adjustment tied to the Argentine entity liquidation
- · FY2026 Adjusted EBITDA declined 4% to $385M, with margin falling to 20.7% from 22.0%
- · Fiscal 2027 guidance implies sales growth of roughly 2-6% and Adjusted EBITDA of $405-$435M versus $385M in FY2026
- · Q4 GAAP loss from continuing operations of $0.36 per diluted share contrasts with $0.73 of income a year earlier
- · Net leverage of 2.3x and $976M total liquidity provide financial flexibility entering fiscal 2027
03-11-2026
Stewards, Inc. (SWRD) filed an 8-K attaching a Securities Purchase Agreement dated October 28, 2026 with CROM Structured Opportunities Fund I, LP, a Delaware limited partnership. The agreement contemplates a convertible note financing ("Offering Notes") under Section 4(a)(2)/Rule 506(b), with proceeds earmarked to fund the acquisition of PIXL at Plantation, a 330-unit multifamily property in Plantation, Florida, and related costs. The agreement includes restrictions on use of proceeds, a right of participation in subsequent placements, and representations covering real estate, EB-5 matters, digital assets, sanctions/AML, and listing compliance.
- · Proceeds are restricted from repaying insider debt, repaying convertible corporate debt, lending to affiliates or other persons, and funding HOPCo-related convertible notes or equity
- · Right of participation in Subsequent Placements applies until Offering Notes are fully extinguished; Planned S-1 Offering participation requires new cash and cannot be satisfied via note conversion or rollover
- · Hawthorne purchase and sale agreement with John E. Swenson Co., Inc. (dated June 5, 2026) was terminated September 17, 2026
- · Company represents no digital asset holdings, but a Dolomite Foundation warrant tranche under a November 3, 2025 agreement is noted as not yet exercisable
- · Company represents Dominican Republic operations comply with AML laws and that no related proceedings are pending or threatened
- · Agreement includes a usury waiver in favor of the Buyer to the extent permitted by law
- · Bracketed figure in the EB-5 representation suggests the redemption cap was not finalized in the filed version
03-11-2026
Syra Health Corp reported Q3 2026 net revenues of $2,557,295, up 51.5% from $1,687,971 in Q3 2025, and net income of $344,610 versus a net loss of $(225,902) a year earlier. For the nine months ended September 30, 2026, net revenues rose 31.6% to $7,225,238 and net income was $835,831 versus a $(761,763) loss. However, Research and development expenses rose sharply from $816 to $46,716 in the quarter, professional services fell 8.6% in the quarter, and Q3 2026 income included a $44,953 tax benefit that was not present in the prior year.
- · Q3 2026 gross margin was approximately 46.3% versus 32.8% in Q3 2025.
- · Nine-month 2026 operating cash flow was $975,023 versus a $(158,554) outflow in the prior-year period.
- · Notes payable rose to $179,272 from $116,386 at December 31, 2025, while nine-month repayments on notes payable were $206,343.
- · Deferred revenue increased to $261,249 from $16,611 at December 31, 2025.
- · Cash and cash equivalents rose to $2,383,413 from $1,614,733 at December 31, 2025, with no investing outflows and no equity raise in the nine months of 2026.
- · Basic EPS for Q3 2026 was $0.02 versus $(0.02) a year earlier; nine-month 2026 basic and diluted EPS was $0.06 versus $(0.06).
03-11-2026
Z Squared Inc. (Nasdaq: ZSQR) elected Jeffery Harris, its Chief Technology Officer, to its Board of Directors effective November 3, 2026, to fill the vacancy left by Michelle Burke's resignation effective May 22, 2026. The Board now has five directors, with three (Adam Sohn, Bryan Fuerst, and Kenneth Cooper) qualifying as independent, so a Board majority remains independent under Nasdaq Rule 5605(b)(1). Mr. Harris will receive no additional director compensation and is not expected to join any Board committee.
- · Harris is an employee and executive officer, so he is not Nasdaq-independent under Rule 5605(a)(2)
- · Harris has been CTO since June 24, 2026, after acquisition of Paradox Data, LLC on September 8, 2026 (now a wholly owned subsidiary)
- · Harris previously served as CEO of Paradox Infrastructure (April 2022 to May 2025) and CEO of Xero Labs (April 2020 to December 2021)
- · Harris's Executive Employment Agreement dated June 24, 2026, was amended by Amendment No. 1 dated August 24, 2026
- · Related-party relationships exist with Paradox Infrastructure LLC and Paradox Energy LLC, previously disclosed in 8-Ks filed August 4, 2026 and September 14, 2026
- · Harris holds an indirect minority interest in Paradox Infrastructure LLC and a 24% membership interest in Paradox Energy LLC
- · Harris does not currently serve, and has not in the past five years served, as a director of any reporting company or registered investment company
03-11-2026
Archrock reported Q3 2026 revenue of $370.8 million, down 3.0% YoY from $382.4 million, as aftermarket services revenue fell 29.4% to $39.7 million on reduced major maintenance demand and lower parts sales. Net income rose 18.6% YoY to $84.5 million (EPS $0.48 vs $0.40) and Adjusted EBITDA grew 3.4% to $228.4 million, while contract operations revenue edged up 1.5% to $331.2 million but adjusted gross margin percentage slipped to 72% from 73%. The company declared a $0.23 quarterly dividend (~10% higher YoY), cut leverage to 2.5x from 3.1x, and reaffirmed full-year 2026 Adjusted EBITDA guidance of $865-$885 million.
- · Total operating horsepower fell to 4.5 million from 4.7 million YoY, reflecting the sale of approximately 112,000 non-strategic operating horsepower.
- · Spot horsepower utilization declined to 94.3% from 96.0% YoY.
- · Adjusted free cash flow dropped 56.4% YoY to $49.6 million, and adjusted free cash flow after dividend fell 88.2% YoY to $9.0 million.
- · No shares were repurchased during Q3 2026; $113.2 million remained available under the repurchase program.
- · Since April 2023 program inception through September 30, 2026, 4,632,263 shares were repurchased for $96.9 million at an average price of $20.91 per share.
- · Q3 2025 results included a $9.9 million net benefit from sales and use tax audit settlements; excluding it, Q3 2025 adjusted gross margin was $229.7 million (70%).
- · Selling, general and administrative expense fell to $26.0 million in Q3 2026 from $37.7 million in Q3 2025.
- · Net cash provided by operating activities was $158.8 million vs $164.5 million YoY.
- · Dividend of $0.23 per share ($0.92 annualized) payable November 10, 2026 to holders of record November 3, 2026.
- · Management cited customer maintenance deferrals and higher lube oil prices as near-term headwinds, offset by cost discipline.
- · Strongest bookings quarter since Q2 2023, with strong Permian Basin bookings.
03-11-2026
Match Group reported Q3 2026 revenue of $891.2M, down 2.5% YoY from $914.3M, while net income rose 8.5% to $174.4M and diluted EPS climbed 17.7% to $0.73, driven by a 10.1% reduction in total operating costs to $622.7M. Nine-month revenue was essentially flat at $2,608.3M (-0.04% YoY), but net income jumped 26.7% to $511.7M. However, selling and marketing (+9.4%) and product development (+14.1%) expenses rose in Q3, and cash fell to $726.2M from $1,027.8M at year-end 2025 while treasury stock purchases continued ($92.1M in Q3, $337.0M YTD).
- · Q3 2026 cost of revenue fell 16.4% YoY to $206.5M from $247.0M
- · Q3 2026 general and administrative expense fell 37.7% YoY to $92.2M from $148.0M
- · Q3 2026 income tax provision rose to $50.4M from $32.9M, raising effective tax rate
- · Interest expense increased to $41.5M in Q3 2026 from $37.0M in Q3 2025
- · Other expense, net was $2.3M in Q3 2026 versus other income of $9.3M in Q3 2025
- · Total shareholders' equity remained negative at $(139.5)M, though improved from $(253.4)M at year-end 2025
- · Retained deficit narrowed to $(5,454.6)M from $(5,966.3)M at December 31, 2025
- · Quarterly dividend raised to $0.20/share in Q3 2026 from $0.19/share in Q3 2025
- · Stock-based compensation was $56.8M in Q3 2026, roughly flat YoY
- · Goodwill stood at $2,340.4M and intangible assets at $157.0M at September 30, 2026
03-11-2026
Palantir reported Q3 2026 revenue of $2.31B, up 95.9% YoY from $1.18B, with net income attributable to common stockholders of $1.13B versus $475.6M a year earlier and diluted EPS of $0.44 vs $0.18. Operating income nearly tripled to $1.08B (46.9% margin) from $393.3M, while gross profit rose 98.2% to $1.93B. However, operating expenses grew faster than gross profit in some lines — sales and marketing jumped 44.5% and R&D rose 52.4% — and other income swung to a $25.8M expense from a $27.5M gain, tempering the otherwise strong quarter.
- · Accumulated deficit shrank to $502.0M from $3.56B at December 31, 2025, reflecting sustained profitability.
- · Total stockholders' equity rose to $11.23B from $7.39B at year-end 2025.
- · Deferred revenue (current) grew to $661.3M from $409.0M, and customer deposits (current) rose to $512.6M from $357.1M.
- · Accounts receivable increased to $1.88B from $1.04B, and nine-month receivables use of cash widened to $843.4M from $423.0M.
- · Nine-month 2026 stock-based compensation was $786.5M, up from $488.6M a year earlier.
- · Other comprehensive income swung to a $12.4M loss from $13.9M income at year-end 2025, driven by a $22.7M unrealized loss on available-for-sale securities.
- · Nine-month 2026 net cash used in investing activities was $1.14B versus $1.83B in 2025.
- · Cash, cash equivalents, and restricted cash ended the period at $3.65B versus $1.64B a year earlier.
03-11-2026
Karyopharm Therapeutics Inc. and affiliate KPT Texas LLC filed a joint prepackaged Chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas (Houston Division), Case No. 26-_____, with joint administration requested. The Prepackaged Plan is supported by Consenting Stakeholders holding 100% of the 1L Term Loan Claims, 1.5L 2028 Notes Claims, 2L 2029 Notes Claims, RIFA Claims, and Existing Preferred Interests, with voting classes 3-6 and a ballot deadline of 4:00 p.m. Central Time on November 30, 2026. General Unsecured Claims are unimpaired and to be paid in full, and the Debtors intend to operate in the ordinary course and pay trade creditors, customers, and employees in full, though confirmation and effectiveness remain subject to Bankruptcy Court approval and conditions precedent with no assurance of completion.
- · Case filed in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division, Case No. 26-_____ (joint administration requested)
- · Voting deadline: 4:00 p.m. prevailing Central Time on November 30, 2026; ballots to be received by claims and balloting agent Stretto, Inc.
- · Claims and balloting agent contact: (866) 270-4922 toll-free in U.S./Canada or +1 (949) 561-0471 international
- · Existing Preferred Interests were issued on September 17, 2026 as consideration under the September Forbearance Agreement
- · Debtors' service address: 85 Wells Avenue, Suite 210, Newton, Massachusetts 02459
- · Solicitation was commenced pre-petition under section 4(a)(2) of the Securities Act and Regulation S, limited to Eligible Holders (QIBs, accredited investors, or non-U.S. persons)
- · Post-petition issuance of Reorganized Parent Common Stock, New Common Stock, and MF CVRs to rely on section 1145(a) of the Bankruptcy Code; New Common Stock issued to Ayrmid equityholders as Merger Consideration and Omisirge Contingent Equity to rely on section 4(a)(2)/Regulation S
- · Certain exhibit portions omitted pursuant to Item 601 of Regulation S-K and marked [***]
- · Disclosure Statement has not been approved by the Bankruptcy Court; confirmation and effectiveness subject to conditions precedent in Article IX of the Prepackaged Plan
03-11-2026
Allegiant Travel Company furnished an 8-K under Regulation FD disclosing unaudited pro forma financial information reflecting its May 13, 2026 acquisition of Sun Country Airlines Holdings, Inc., presented as if the deal closed January 1, 2025. The pro forma statements cover six quarterly periods (Q1 2025 through Q2 2026) and the full year 2025, attached as Exhibit 99.1. The filing contains no actual financial figures or performance metrics in the body text, so no period-over-period comparisons can be assessed from this document alone.
- · Acquisition of Sun Country Airlines Holdings, Inc. completed May 13, 2026
- · Pro forma information assumes the transaction closed January 1, 2025
- · Pro forma periods: three months ended March 31, 2025; June 30, 2025; September 30, 2025; December 31, 2025; March 31, 2026; June 30, 2026; and year ended December 31, 2025
- · Information furnished under Item 7.01 is not deemed 'filed' under Section 18 of the Exchange Act and not incorporated by reference
- · Exhibit 99.1 contains the pro forma statements; no actual figures disclosed in the 8-K body
- · Company incorporated in Nevada; principal offices at 1201 North Town Center Drive, Las Vegas, NV 89144
- · Commission File Number 001-33166; IRS EIN 20-4745737
03-11-2026
EagleRock Land reported Q3 2026 revenue of $43.3 million and net income of $11.3 million, with Adjusted EBITDA of $34.0 million (78.5% margin). Q3 revenue declined from $46.8 million normalized in Q2, and Resource Sales were weaker in New Mexico, while the company raised full-year 2026 Adjusted EBITDA guidance to $133-137 million on Intrepid Ranch and organic growth. It also announced a Double Eagle V acreage dedication of about 35,000 acres and closed Midland Basin bolt-on acquisitions of about 2,000 acres for approximately $15.4 million.
- · Q3 2026 net income of $11.3M is inflated relative to the operating picture: income from operations was $12.5M, but Nine Months 2026 shows a net loss of $22.9M driven by $90.8M of G&A and a $20.4M gain on debt extinguishment.
- · Net income attributable to EagleRock Land, LLC was only $2.1M in Q3 2026, with $9.2M attributable to noncontrolling interest.
- · Q3 2026 Resource sales (consolidated) fell about 20% YoY to $9.6M from $11.9M, and Resource Sales from related party are reported separately.
- · Nine-month 2026 G&A expense of $90.8M versus $7.1M in the prior-year period warrants scrutiny.
- · Q3 2026 depreciation and amortization rose to $15.9M from $4.6M a year earlier, reflecting the acquisitions.
- · Net debt of $58M is accompanied by an expected ~$10M monthly debt paydown, with ~$16M of October revolver borrowings to fund bolt-ons.
03-11-2026
Ligand Pharmaceuticals (reporting person) amended its Schedule 13D to disclose a $33.75 million purchase of Pelthos Series B Convertible Preferred Stock and warrants under a Securities Purchase Agreement, alongside Pelthos's October 30, 2026 Merger Agreement with Castle Creek Biosciences (Merger Partner). Ligand currently beneficially owns 5,189,177.1 shares of Common Stock, representing 49.9% of outstanding shares, with beneficial ownership capped at 49.9% via conversion blockers. The transactions are not yet closed and remain subject to closing conditions, including stockholder approvals, a Form S-4 effectiveness, HSR clearance, and NYSE American listing approval.
- · Ligand's beneficial ownership is capped at 49.9% of outstanding Common Stock, and the Series B and warrants carry a 49.99% maximum, so the cap rises if Ligand elects to increase its limit (subject to a 61-day delay).
- · Ligand's Series B and warrant acquisitions have not yet closed; the 5,189,177.1 share figure excludes Series B, warrants, and Merger shares.
- · Board composition expands from eight to ten directors post-merger, with two directors designated by Castle Creek; Ligand-affiliated directors Davis and Baxter may influence control.
- · The First Merger must close by February 1, 2027 (extendable to March 31, 2027), otherwise either party may terminate.
- · Warrants become exercisable 180 days after closing of the Mergers and Concurrent Financing, at a nominal $0.0001 exercise price.
- · Pelthos intends to use Concurrent Financing proceeds to repay Castle Creek indebtedness and for working capital; Ligand's royalty financing with Castle Creek remains in place with an intercreditor agreement.
03-11-2026
Fusemachines reported Q3 2026 revenue of $1.845M, up 3.0% YoY from $1.792M, but gross profit slipped 1.5% to $0.981M as cost of revenue rose 8.5%. Operating expenses surged 57.7% YoY to $3.295M (driven by G&A up 62.6% and R&D up 73.3%), widening operating loss to $2.314M from $1.094M and net loss to $4.623M from $1.174M, exacerbated by a $2.212M loss on the forward purchase derivative liability. Nine-month revenue declined 4.5% to $5.518M while net loss widened to $8.344M from $5.213M, and cash fell to $1.454M from $4.221M at year-end 2025.
- · Net loss per common share was $(0.15) in Q3 2026, flat versus $(0.15) in Q3 2025, despite the larger net loss, due to weighted-average shares rising to 30,586,609 from 7,672,654
- · Nine-month net loss per share improved to $(0.29) from $(0.70) on higher share count
- · Gain on extinguishment of payable of $612K in 9M 2026 and $105K in Q3 2026
- · Interest expense rose to $353K in Q3 2026 from $74K in Q3 2025
- · Forward purchase derivative liability fell to $708K at Sep 30, 2026 from $9,692K at Dec 31, 2025
- · Company issued 2,138,935 common shares to settle $1,298K of outstanding vendor invoices and 530,902 shares to settle $460K of employee severance
- · Accounts payable of $4.527M and accrued expenses of $4.734M exceed cash of $1.454M as of September 30, 2026
- · Deemed dividend of $84K related to Shortfall Warrants modification in 9M 2026
- · Convertible notes payable, current of $1,245K newly recorded at Sep 30, 2026
03-11-2026
Crown Equity Holdings filed its Q3 2026 10-Q reporting revenue of $102 for the three months ended September 30, 2026, down 63% from $279 a year earlier, while nine-month revenue fell 56% to $256 from $577. The quarterly net loss narrowed to $24,225 from $31,798, but the nine-month net loss widened to $93,715 from $59,380 as G&A expenses rose 17% and interest expense climbed 48%. Stockholders' deficit deepened to $407,778 from $314,062 at year-end 2025, with cash of just $1,137 and total liabilities of $417,495, raising going-concern-type liquidity concerns.
- · Cash fell 50% to $1,137 from $2,272 at December 31, 2025, while total liabilities of $417,495 far exceed total assets of $9,717.
- · Related-party notes payable rose to $232,443 from $169,712, and related-party accounts payable grew to $78,835 from $65,742.
- · Nine-month 2026 net cash used in operating activities widened to $63,866 from $27,671, funded by $62,731 of related-party borrowings versus $18,905 a year earlier.
- · No common stock was issued for cash in the first nine months of 2026, versus $8,000 (11,000 shares) in the prior-year period.
- · Prior-year nine-month results included a $38,175 gain on debt conversion and a $19,579 loss on AP conversion; no comparable items in 2026.
- · Weighted average diluted shares rose to 15,936,480 from 15,888,396 in the nine-month comparison.
- · Net loss per share was $(0.00) in all periods presented.
03-11-2026
News Corporation filed an 8-K on November 3, 2026 disclosing routine daily ASX notifications (Exhibits 99.1 and 99.2) related to its existing stock repurchase program, under which it is authorized to acquire up to $1 billion in aggregate of Class A and Class B common stock. The filing contains no new repurchase authorization, no transaction amounts, and no financial results — it is a procedural disclosure of information already provided to the Australian Securities Exchange.
- · Exhibits 99.1 and 99.2 are copies of information provided to the ASX on the dates noted therein; no specific transaction volumes or prices are disclosed in the filing text
- · The repurchase program authorization of up to $1 billion was previously reported and is not newly established by this filing
- · Company is required under ASX rules to disclose repurchase transactions on a daily basis, if any
- · Filing includes standard forward-looking statement disclaimers regarding intent to repurchase shares from time to time
- · Signed by Michael L. Bunder, Senior Vice President, Deputy General Counsel and Corporate Secretary, dated November 3, 2026
03-11-2026
Mercer International entered restructuring support agreements with holders of more than 87% of its Senior Notes and a majority of its common shareholders to implement a prepackaged Chapter 11 recapitalization addressing $1.275 billion of Senior Notes. The deal exchanges approximately $1.1 billion of notes (about 88% of Senior Note debt) for equity, eliminates roughly $96 million of annual cash interest, and raises $400 million of new money via a fully backstopped rights offering of $420 million principal of new senior secured notes. However, existing common stock will be cancelled and holders receive only about 8.5% of new common stock and 3.5% of new convertible preferred, with Nasdaq delisting expected and no bond maturities until 2031.
- · New notes mature four years and 364 days after issuance with no scheduled amortization; interest may be paid substantially in kind for the first two years
- · No bond maturities until 2031
- · Plan confirmation expected within approximately 45 days of filing; recapitalization targeted for completion by end of 2026
- · Chapter 11 cases to be filed in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division
- · Trade and other general unsecured claims are unimpaired and to be paid in full
- · Mercer elected not to make the October 1, 2026 interest payment on its 12.875% Senior Notes due 2028 and on October 30, 2026 extended the grace period from 30 to 90 calendar days via supplemental indenture
- · Mercer expects Nasdaq to notify it of a determination to delist the common stock; shares may trade over-the-counter
- · Company intends to apply to list new common stock on Nasdaq or another national securities exchange after the effective date
- · Existing credit facilities expected to be repaid in whole or in part and replaced with up to $300 million of new revolving commitments
03-11-2026
Aimei Health Technology Co., Ltd. issued a $34,330.96 promissory note dated October 5, 2026 to affiliate Aimei Investment Ltd, disclosed via 8-K/A under Item 2.03. The note carries no interest, is payable at the closing of a business combination, and is convertible into private units at $10.00 per unit (each unit comprising one ordinary share plus one-fifth of a right). The Payee waives all claims against the IPO trust account, so repayment depends on completing a Business Combination or other non-trust funds.
- · Note dated October 5, 2026; filing date November 3, 2026 (8-K/A).
- · Maturity Date is the date the Maker consummates a Business Combination; principal may be prepaid without penalty.
- · Conversion requires written notice at least two business days prior to closing of a Business Combination; no fractional units issued (cash paid instead).
- · Events of Default include payment failure beyond 5 business days of Maturity, voluntary/involuntary bankruptcy (60-day unstayed order), breach of obligations, and unlawfulness.
- · Payee waives all claims against IPO trust account funds; if no Business Combination, note repaid only from non-trust amounts.
- · Governing law: New York; no personal liability for officers, directors, employees or stockholders.
03-11-2026
Black Stone Minerals reported Q3 2026 net income of $52.4 million, down sharply from $106.4 million in Q2 2026 and $91.7 million in Q3 2025, largely due to a $30.2 million loss on commodity derivatives versus gains of $26.8 million and $27.3 million in the prior periods. Adjusted EBITDA rose to $104.1 million (+14% QoQ, +18% YoY) and distributable cash flow reached $93.0 million, while total production of 35.6 MBoe/d increased 6% QoQ but declined 2% YoY from 36.3 MBoe/d. The Board raised the quarterly distribution 9% QoQ and 17% since Q1 2026 to $0.35 per unit (1.25x coverage), and the Partnership expanded its Caturus development agreement by 730,000 gross acres to 950,000 total acres.
- · Working-interest production fell to 1.1 MBoe/d in Q3 2026 from 1.6 MBoe/d in Q3 2025, a 31% YoY decline
- · Distribution coverage of 1.25x; distribution payable November 13, 2026 to unitholders of record November 6, 2026
- · Caturus expanded agreement: first additional area pilot well expected by Q1 2028, ramping to ~12 gross wells annually by 2034; second area pilot by end of 2031, ramping to ~12 gross wells annually by 2038; minimum annual commitments rise from 8,000 to 33,600 net lateral feet
- · Revenant amendment increased 2027 drilling commitment by 7,000 gross lateral feet and extended second-AOI requirement to 2029
- · Adamas: 7 gross (0.7 net) wells turned to sales in Q3 2026; 9 gross (0.9 net) of prior-year wells on sales, 4 gross (0.4 net) expected in Q4 2026
- · Blue Arrow: 10 gross (0.9 net) of 25 gross wells turned to sales as of September 30, 2026
- · Hedge position: oil swaps ~$64.39–$71.59/bbl through 4Q28; natural gas swaps ~$3.70–$3.84/MMbtu through 4Q28
- · Next borrowing base redetermination scheduled April 2027; in compliance with all credit facility covenants
- · Conference call November 3, 2026 at 9:00 a.m. Central Time
03-11-2026
Xcel Brands, Inc. (XELB) filed a definitive DEF 14A proxy statement dated November 3, 2026, for its 2026 Annual Meeting of Stockholders to be held December 18, 2026. Stockholders will vote on electing five directors, ratifying Wolf & Company, PC as auditor for fiscal 2026, increasing shares reserved under the 2021 Equity Incentive Plan from 1,150,000 to 1,800,000 (an increase of 650,000), and approving issuance of more than 19.99% of outstanding common stock upon conversion of certain secured promissory notes following an event of default. The Board unanimously recommends FOR on all proposals. The company had 6,908,839 shares outstanding as of the October 27, 2026 record date.
- · Proposal IV would authorize issuance above the 19.99% Nasdaq-style threshold upon conversion of secured promissory notes triggered by an event of default, signaling existing debt-related stress
- · Company elected the notice-only option for proxy delivery; materials available at www.cstproxy.com/xcelbrands/2026
- · Director elections require a majority of votes present; abstentions and broker non-votes do not affect outcome
- · Brokers may not use discretionary authority to vote on the auditor ratification without client instructions
- · Meeting attendance limited to record-date stockholders or authorized representatives with evidence of ownership
03-11-2026
Pinnacle West Capital (PNW) reported Q3 2026 net income attributable to common shareholders of $434.2 million ($3.49 diluted EPS), up 5.1% from $413.2 million ($3.39 diluted EPS) in Q3 2025, and nine-month net income of $645.7 million ($5.20 diluted EPS), up 7.4% YoY. Operating revenues grew 8.4% in the quarter to $1,972.7 million, but operating and maintenance expense fell 1.7% and interest expense rose 12.1%, and total other income declined 15.0% in the quarter, tempering the earnings gains.
- · Q3 2026 total operating expenses rose 9.1% to $1,351.9M, driven by fuel and purchased power up 15.6% to $758.0M, partly offset by lower O&M
- · Depreciation and amortization rose 8.0% in Q3 to $242.5M, and 5.4% over nine months to $725.6M
- · Construction work in progress rose to $2,506.8M at September 30, 2026 from $1,649.5M at year-end 2025 (up 52.0%), signaling heavy capital investment
- · Short-term borrowings fell to $438.6M from $757.0M, while long-term debt (less current maturities) rose 10.4% to $10,164.4M
- · Operating lease right-of-use assets rose 47.5% to $5,383.8M, and operating lease liabilities (non-current) rose 50.1% to $5,329.2M
- · Nine-month cash provided by operating activities grew 1.8% to $1,352.4M, while capital expenditures rose 7.0% to $2,091.6M
- · Deferred fuel and purchased power regulatory asset of $149.1M at year-end 2025 was reversed to a $93.8M liability at September 30, 2026
- · Common dividends payable of $110.0M at year-end 2025 was fully paid out, leaving no dividends payable at quarter-end
- · Common stock issued rose to 121,244,202 shares from 120,950,839 at year-end, reflecting modest equity issuance
- · Cash and cash equivalents ended at $11.1M, down sharply from $30.9M a year earlier, despite a 2026 year-end cash balance of $6.6M
03-11-2026
OBAI (Our Bond, Inc., referred to in the filing as TG-17, Inc.) filed an amended and restated Certificate of Designations for its Series G Convertible Preferred Stock, approved by the Board and requisite Series G holders on November 1, 2026. The authorized Preferred Shares total 1,813,101 at $0.0001 par value, with a conversion price of $2.0265 per share, a 24.0% dividend rate that applies during any Triggering Event, and cumulative, daily-accruing dividends compounded annually. The filing is primarily a governance and capital-structure document, and the exhibit does not disclose the financing proceeds or investor identities.
- · Original Series G Certificate of Designations was filed with the Nevada Secretary of State on June 16, 2026; this amended and restated version was adopted November 1, 2026.
- · Dividends accrue from the Closing Date, with accrued amounts through closing subject to written waivers from the applicable Holders.
- · Preferred Shares have no maturity date and holders have no right to require cash redemption.
- · Company cannot create senior or pari passu securities with respect to dividends or liquidation without the protections in the instrument.
- · Conversion failure penalty: 2% per day of the value of undelivered shares, for up to 10 Trading Days, plus buy-in rights for holders.
- · Filing items 1.01, 3.02, 5.03 and 9.01 indicate a material agreement, unregistered equity sale, and charter/bylaw amendment.
03-11-2026
Privium Fund Management B.V. (Amsterdam) filed its Form 13F-HR for the quarter ended September 30, 2026, reporting 58 holdings with a total reported value of approximately $5.16 billion ($515,534,819 thousand, reported in USD thousands). The portfolio is concentrated in biotechnology and gene-therapy names, alongside large-cap technology (NVIDIA, Tesla, Amazon, Palantir, Shopify) and energy/materials positions. Because a 13F reports only long equity positions as of quarter-end, the filing shows holdings only and does not indicate buy/sell activity versus the prior quarter.
- · Largest reported positions by value include Space Exploration Technologies (~$1.6B-scale value at 250,000 shares, per table), Tesla (225,000 shares), NVIDIA (81,000 shares) and Palantir (200,000 shares, ~$374M).
- · Heavy biotech/gene-therapy concentration, including multiple positions in CRISPR Therapeutics, Denali, Sarepta, Ultragenyx, Voyager, Taysha and Cartesian Therapeutics.
- · Positions are reported solely with sole investment and voting authority (SOLE), with no shared or other-manager attribution.
- · The filing reports no comparative prior-quarter data, so quarter-over-quarter changes in position size cannot be determined from this document.
03-11-2026
Pfizer reported Q3 2026 total revenues of $16,583 Million, down 0.4% YoY from $16,654 Million, while net income attributable to Pfizer shareholders fell 8.4% to $3,242 Million from $3,541 Million. Nine-month revenues rose 2.3% to $46,067 Million, but nine-month net income fell 39.7% to $5,681 Million, largely reflecting $4,487 Million of asset write-offs and impairments and a $1,870 Million gain on the ViiV investment sale. Mixed performance: product revenues declined while alliance and royalty revenues grew.
- · Q3 2026 Selling, informational and administrative expenses rose 2.9% to $3,279 Million and R&D expenses rose 18.4% to $3,016 Million, compressing operating margins.
- · Q3 2026 Other (income)/deductions was an expense of $288 Million versus $517 Million a year earlier, while nine-month Other (income)/deductions was an expense of $4,866 Million versus $2,210 Million, driven by impairments.
- · Q3 2026 effective tax provision was $134 Million versus a $216 Million benefit in Q3 2025; nine-month provision was $188 Million versus a $264 Million benefit.
- · Q3 2026 acquired IPR&D expense fell to $669 Million from $1,390 Million, and amortization of intangibles declined to $1,128 Million from $1,223 Million.
- · Cash dividends paid were $7,347 Million for nine months, roughly in line with $7,326 Million a year earlier; no dividends payable were outstanding at September 27, 2026 versus $2,445 Million at year-end 2025.
- · Trade accounts receivable rose to $14,192 Million from $11,874 Million at year-end 2025, a 19.5% increase, while inventories declined to $10,022 Million from $10,654 Million.
- · Long-term debt declined to $59,997 Million from $61,641 Million, and nine-month payments on long-term debt were $1,250 Million; short-term borrowings fell to $2,674 Million from $3,154 Million.
- · Cash and cash equivalents rose to $1,824 Million from $1,142 Million at year-end 2025.
- · Pfizer's shareholders' equity increased to $89,001 Million from $86,476 Million, supported by $5,681 Million of net income and $1,100 Million of OCI, net of $4,902 Million of dividends.
- · Q3 2026 comprehensive income attributable to Pfizer was $3,491 Million versus $3,913 Million a year earlier.
03-11-2026
TOP Financial Group Ltd issued a Regulation FD press release addressing recent unusual fluctuations in its stock price, stating that operations are progressing normally and that it is not aware of any material undisclosed developments that would explain the volatility. The company reaffirmed its Houston global headquarters, its planned AI Research and Development Center in Silicon Valley, and its U.S. expansion strategy, while noting that no specific financial results were disclosed in this filing.
- · Company states it is not aware of any material, undisclosed corporate developments that would account for the recent stock price volatility
- · Global headquarters established in Houston, Texas (4201 Main Street, Suite 200)
- · Company is 'actively planning' the Silicon Valley AI R&D Center; no timeline, budget, or headcount was disclosed
- · Company is an emerging growth company (per cover page); Class A Ordinary Shares trade on Nasdaq Capital Market under symbol TOP
- · Company is a Cayman Islands exempted company, with operating subsidiaries licensed in Singapore, Australia, and Hong Kong
Get daily alerts with 13 investment signals, 11 risk alerts, 10 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Filings Daily Market Digest
🇺🇸 More from United States
View all →November 04, 2026
US Pre-Market SEC Filings Roundup — November 04, 2026
US Pre-Market SEC Filings Roundup
November 04, 2026
US Merger & Acquisition SEC Filings — November 04, 2026
US Merger & Acquisition SEC Filings
November 03, 2026
US Pre-Market SEC Filings Roundup — November 03, 2026
US Pre-Market SEC Filings Roundup
November 03, 2026
US Executive Compensation Proxy SEC Filings — November 03, 2026
US Executive Compensation Proxy SEC Filings